These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 28167539)

  • 41. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
    Keck ZY; Enterlein SG; Howell KA; Vu H; Shulenin S; Warfield KL; Froude JW; Araghi N; Douglas R; Biggins J; Lear-Rooney CM; Wirchnianski AS; Lau P; Wang Y; Herbert AS; Dye JM; Glass PJ; Holtsberg FW; Foung SK; Aman MJ
    J Virol; 2016 Jan; 90(1):279-91. PubMed ID: 26468532
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative Analysis of Host Cell Entry of Ebola Virus From Sierra Leone, 2014, and Zaire, 1976.
    Hofmann-Winkler H; Gnirß K; Wrensch F; Pöhlmann S
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S172-80. PubMed ID: 25840443
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel cyclo-peptides inhibit Ebola pseudotyped virus entry by targeting primed GP protein.
    Li Q; Ma L; Yi D; Wang H; Wang J; Zhang Y; Guo Y; Li X; Zhou J; Shi Y; Gao GF; Cen S
    Antiviral Res; 2018 Jul; 155():1-11. PubMed ID: 29709562
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Detection of Ebola virus envelope using monoclonal and polyclonal antibodies in ELISA, surface plasmon resonance and a quartz crystal microbalance immunosensor.
    Yu JS; Liao HX; Gerdon AE; Huffman B; Scearce RM; McAdams M; Alam SM; Popernack PM; Sullivan NJ; Wright D; Cliffel DE; Nabel GJ; Haynes BF
    J Virol Methods; 2006 Nov; 137(2):219-28. PubMed ID: 16857271
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Enhancement of Ebola Virus Infection via Ficolin-1 Interaction with the Mucin Domain of GP Glycoprotein.
    Favier AL; Gout E; Reynard O; Ferraris O; Kleman JP; Volchkov V; Peyrefitte C; Thielens NM
    J Virol; 2016 Jun; 90(11):5256-5269. PubMed ID: 26984723
    [TBL] [Abstract][Full Text] [Related]  

  • 46. VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection.
    Williams KJ; Qiu X; Fernando L; Jones SM; Alimonti JB
    Viral Immunol; 2015 Feb; 28(1):51-61. PubMed ID: 25494457
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Involvement of viral envelope GP2 in Ebola virus entry into cells expressing the macrophage galactose-type C-type lectin.
    Usami K; Matsuno K; Igarashi M; Denda-Nagai K; Takada A; Irimura T
    Biochem Biophys Res Commun; 2011 Apr; 407(1):74-8. PubMed ID: 21362405
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multiple cationic amphiphiles induce a Niemann-Pick C phenotype and inhibit Ebola virus entry and infection.
    Shoemaker CJ; Schornberg KL; Delos SE; Scully C; Pajouhesh H; Olinger GG; Johansen LM; White JM
    PLoS One; 2013; 8(2):e56265. PubMed ID: 23441171
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Establishment of a cell-based filovirus entry inhibitor evaluation system].
    Chen Q; Guo Y
    Yao Xue Xue Bao; 2015 Dec; 50(12):1538-44. PubMed ID: 27169274
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of a Sensitive and Specific Serological Assay Based on Luminex Technology for Detection of Antibodies to Zaire Ebola Virus.
    Ayouba A; Touré A; Butel C; Keita AK; Binetruy F; Sow MS; Foulongne V; Delaporte E; Peeters M
    J Clin Microbiol; 2017 Jan; 55(1):165-176. PubMed ID: 27795350
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of potential inhibitors of protein-protein interaction useful to fight against Ebola and other highly pathogenic viruses.
    Lasala F; García-Rubia A; Requena C; Galindo I; Cuesta-Geijo MA; García-Dorival I; Bueno P; Labiod N; Luczkowiak J; Martinez A; Campillo NE; Alonso C; Delgado R; Gil C
    Antiviral Res; 2021 Feb; 186():105011. PubMed ID: 33428961
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FDA-approved selective estrogen receptor modulators inhibit Ebola virus infection.
    Johansen LM; Brannan JM; Delos SE; Shoemaker CJ; Stossel A; Lear C; Hoffstrom BG; Dewald LE; Schornberg KL; Scully C; Lehár J; Hensley LE; White JM; Olinger GG
    Sci Transl Med; 2013 Jun; 5(190):190ra79. PubMed ID: 23785035
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modulation of virion incorporation of Ebolavirus glycoprotein: effects on attachment, cellular entry and neutralization.
    Marzi A; Wegele A; Pöhlmann S
    Virology; 2006 Sep; 352(2):345-56. PubMed ID: 16777170
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Characterization of Ebola convalescent plasma donor immune response and psoralen treated plasma in the United States.
    Dean CL; Hooper JW; Dye JM; Zak SE; Koepsell SA; Corash L; Benjamin RJ; Kwilas S; Bonds S; Winkler AM; Kraft CS
    Transfusion; 2020 May; 60(5):1024-1031. PubMed ID: 32129478
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro.
    Sheng M; Zhong Y; Chen Y; Du J; Ju X; Zhao C; Zhang G; Zhang L; Liu K; Yang N; Xie P; Li D; Zhang MQ; Jiang C
    Sci China Life Sci; 2014 Oct; 57(10):959-72. PubMed ID: 25218824
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiviral effect of ranpirnase against Ebola virus.
    Hodge T; Draper K; Brasel T; Freiberg A; Squiquera L; Sidransky D; Sulley J; Taxman DJ
    Antiviral Res; 2016 Aug; 132():210-8. PubMed ID: 27350309
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evidence for distinct mechanisms of small molecule inhibitors of filovirus entry.
    Schafer A; Xiong R; Cooper L; Nowar R; Lee H; Li Y; Ramirez BE; Peet NP; Caffrey M; Thatcher GRJ; Saphire EO; Cheng H; Rong L
    PLoS Pathog; 2021 Feb; 17(2):e1009312. PubMed ID: 33539432
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Repurposing Pyramax®, quinacrine and tilorone as treatments for Ebola virus disease.
    Lane TR; Dyall J; Mercer L; Goodin C; Foil DH; Zhou H; Postnikova E; Liang JY; Holbrook MR; Madrid PB; Ekins S
    Antiviral Res; 2020 Oct; 182():104908. PubMed ID: 32798602
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of a small-molecule entry inhibitor for filoviruses.
    Basu A; Li B; Mills DM; Panchal RG; Cardinale SC; Butler MM; Peet NP; Majgier-Baranowska H; Williams JD; Patel I; Moir DT; Bavari S; Ray R; Farzan MR; Rong L; Bowlin TL
    J Virol; 2011 Apr; 85(7):3106-19. PubMed ID: 21270170
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of Ebola Virus by a Molecularly Engineered Banana Lectin.
    Covés-Datson EM; Dyall J; DeWald LE; King SR; Dube D; Legendre M; Nelson E; Drews KC; Gross R; Gerhardt DM; Torzewski L; Postnikova E; Liang JY; Ban B; Shetty J; Hensley LE; Jahrling PB; Olinger GG; White JM; Markovitz DM
    PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007595. PubMed ID: 31356611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.